DEA Telehealth Prescribing Cliff: What Psychiatry Practices Must Prepare for in 2027

What Is the DEA Telehealth Prescribing Cliff?

As of October 2026, the DEA’s temporary telemedicine flexibilities for prescribing controlled substances are set to expire on December 31, 2026, with no finalized permanent rule in place. If the flexibilities lapse without a replacement, the Ryan Haight Act’s default requirement resumes on January 1, 2027: a qualifying in-person medical evaluation before any controlled substance can be prescribed via telehealth. For psychiatry practices that prescribe stimulants, benzodiazepines, or sleep medications through virtual visits, this deadline is less than 75 days away.

• What expires: The fourth temporary DEA/HHS extension allowing Schedule II through V controlled substance prescribing via telehealth without a prior in-person visit ends December 31, 2026.
• What is pending: The DEA submitted a final special registration rule to the White House Office of Information and Regulatory Affairs (OIRA) on August 25, 2026. As of October 2026, that rule has not been published.
• What is at stake: Any psychiatry practice prescribing ADHD stimulants, benzodiazepines, or other controlled substances via telehealth without first seeing the patient in person could lose the legal authority to do so on January 1, 2027.

Why Does This Matter for Psychiatry Specifically?

Psychiatry is the specialty most exposed to this deadline. No other medical specialty prescribes controlled substances via telehealth at the same volume and frequency as psychiatry practices, and no other specialty has built as much of its operational model around virtual prescribing since the pandemic.

The medications at issue are core to outpatient psychiatric care. Schedule II stimulants such as amphetamine salts (Adderall) and lisdexamfetamine (Vyvanse) are the standard pharmacological treatment for ADHD. Schedule IV benzodiazepines such as alprazolam and lorazepam are prescribed for anxiety disorders. Schedule IV sleep medications including zolpidem are prescribed for insomnia. All of these fall under the DEA’s temporary telehealth prescribing authority, and all of them require a qualifying in-person evaluation under the Ryan Haight Act if the flexibilities lapse.

The most common issue we see providers run into when they come to us for billing help is that their telehealth workflows were built during the pandemic and never updated to account for regulatory changes. The DEA has extended these flexibilities four times since 2023, and each extension reinforced the assumption that virtual prescribing would continue indefinitely. That assumption now has a hard expiration date, and the billing consequences of prescribing without proper authority extend far beyond a claim denial.

For the Medicare telehealth billing rules that run alongside the DEA prescribing rules, see our guide to psychiatry telehealth billing under the 2027 Medicare rules. The two frameworks overlap but are not the same: Medicare determines whether a telehealth visit is reimbursable, and the DEA determines whether a controlled substance can legally be prescribed during that visit.

What Happens If the DEA Flexibilities Expire?

If December 31, 2026, passes without a published permanent rule or a fifth temporary extension, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 resumes as the governing law. Under the Ryan Haight Act, a practitioner generally may not prescribe a controlled substance by means of the internet (which includes telehealth) unless the patient has had at least one in-person medical evaluation conducted by the prescribing practitioner or a practitioner acting within the same practice.

That means a psychiatrist who has been prescribing a Schedule II stimulant to a patient seen only via video since 2020 would need to conduct an in-person evaluation before writing the next prescription. For practices with large virtual patient panels, the operational disruption would be significant: scheduling in-person visits for potentially hundreds of patients within a narrow window, or pausing prescriptions until the visit occurs.

There are limited exceptions under the Ryan Haight Act, including prescriptions issued in a hospital or clinic, by a practitioner in the physical presence of the patient, or by a practitioner acting within the Indian Health Service. But none of these exceptions covers the standard outpatient telehealth encounter that most psychiatry practices rely on.

The billing impact is equally direct. A controlled substance prescription issued without proper prescribing authority is not a documentation gap that can be corrected on appeal. It is a compliance event. Payers that discover the prescription lacked legal basis can deny the associated evaluation and management claim, recoup previously paid claims, and in severe cases refer the matter for fraud review. The risk is not theoretical: the DEA and OIG have both signaled increased scrutiny of telehealth prescribing compliance.

What Is the DEA Special Registration Rule?

The DEA proposed a Special Registration for Telemedicine framework in January 2025. The proposed rule would create new registration categories that allow qualified practitioners to prescribe controlled substances via telehealth under specific conditions, including additional safeguards, recordkeeping, reporting requirements, and restrictions on prescribing quantities. It would also impose requirements on direct-to-consumer telemedicine platforms that facilitate controlled substance prescribing.

The DEA submitted a final version of this rule to the White House Office of Information and Regulatory Affairs (OIRA) for review on August 25, 2026. OIRA review is the last step before a federal rule is published in the Federal Register. The review period typically takes 30 to 90 days, but there is no statutory deadline, and OIRA can extend its review.

As of October 2026, the final rule has not been published. If OIRA completes its review and the DEA publishes the final rule before December 31, 2026, the new permanent framework would replace the temporary extension and provide a defined path forward. If the rule is delayed past the expiration date, psychiatry practices face the gap described above unless the DEA issues a fifth temporary extension.

In our experience matching providers with billing partners, the billing companies that handle telehealth-heavy psychiatry practices are already mapping out both scenarios: one where the permanent rule publishes on time, and one where it does not. The practices that wait to see what happens will be the ones scrambling in January.

What Should Psychiatry Practices Do Before January 1, 2027?

These steps apply to any psychiatry practice that prescribes Schedule II through V controlled substances via telehealth. Complete them before the December 31 deadline regardless of whether the permanent rule publishes, because either outcome requires preparation.

• Audit your virtual prescribing panel. Identify every patient currently receiving a controlled substance prescription who has never had an in-person visit with the prescribing practitioner.
• Prioritize in-person scheduling for high-risk patients. Start with Schedule II prescriptions (stimulants) because these carry the strictest prescribing requirements under the Ryan Haight Act and the highest audit risk.
• Document the telehealth modality on every encounter. Confirm that every telehealth visit involving a controlled substance is documented with the correct place of service code (POS 10 for home, POS 02 for other telehealth site) and the appropriate modifier (95 for audio-video, FQ for audio-only behavioral health under Medicare).
• Separate the DEA rules from the Medicare rules. Medicare’s telehealth flexibilities for behavioral health were extended through December 31, 2027, under the Consolidated Appropriations Act of 2026. That extension covers reimbursement. It does not override the DEA’s prescribing authority rules. A telehealth visit can be billable under Medicare and still lack DEA prescribing authority if the flexibilities expire.
• Monitor the Federal Register weekly. Watch for the publication of the DEA special registration final rule and any announcement of a fifth temporary extension. CMS MLN Connects and the DEA Diversion Control Division website are the primary sources.
• Update your compliance training. Ensure that every prescribing clinician in the practice understands the distinction between Medicare telehealth reimbursement and DEA controlled substance prescribing authority, and knows the practice’s contingency plan for January 1.

Providers often come to us after a compliance event that could have been prevented with the right workflow in place. The DEA prescribing cliff is exactly the kind of issue where the cost of preparation is a fraction of the cost of getting caught without it.

How the DEA Rules Differ from Medicare Telehealth Rules

This is the distinction that trips up more psychiatry practices than any other billing issue. Medicare and the DEA govern different questions, and a telehealth visit can satisfy one set of rules while violating the other.

A psychiatrist can bill Medicare for a psychiatric diagnostic evaluation (CPT 90792) delivered via telehealth in 2027 regardless of what happens with the DEA rule. Medicare will reimburse the visit. But if the DEA flexibilities have lapsed and the psychiatrist prescribes a Schedule II stimulant during that visit to a patient who has never been seen in person, the prescription itself lacks legal authority under the Ryan Haight Act, even though the visit was reimbursable.

Across the billing companies we vet, the ones that specialize in psychiatry track both rule sets on parallel timelines. The ones that treat telehealth as a single regulatory question are the ones whose clients end up exposed. For more on the Medicare side of the equation, see our coverage of the 2027 telehealth billing changes for psychiatry.

Frequently Asked Questions

Next Steps

• For Medicare telehealth billing rules that run alongside the DEA prescribing rules, see our guide to psychiatry telehealth billing under 2027 Medicare rules.
• For the collaborative care billing changes that affect integrated behavioral health practices, see our CoCM G-code update.
• Need a billing partner who tracks both DEA and CMS rule changes and prepares your practice before deadlines hit? Get matched with vetted psychiatry billing companies at no cost.